OP
SRPT icon

ORG Partners’s Sarepta Therapeutics SRPT Stock Holding History

ORG Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,000
Closed -$243K – 1581
2024
Q4 		$243K Buy
2,000
+300
+18% +$36.8K 0.03% 290
2024
Q3 		$212K Hold
1,700
– – 0.03% 272
2024
Q2 		$266K Buy
+1,700
New +$218K 0.03% 352

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ORG Partners's SRPT Position: Q1 2025 in Review

ORG Partners sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 2,000 shares — an estimated $243K sold.

ORG Partners first reported a position in SRPT in Q2 2024 and held it in 3 quarters. The position peaked at $266K in Q2 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • ORG Partners reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • ORG Partners sold 2,000 Sarepta Therapeutics shares in Q1 2025, an estimated $243K.
  • ORG Partners first reported a position in Sarepta Therapeutics in Q2 2024 and held it in 3 quarters.
  • ORG Partners's Sarepta Therapeutics position peaked at $266K in Q2 2024.
  • 430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on ORG Partners's 13F filing for Q1 2025, filed 21 Apr 2025.